Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B

ABSTRACT Background MST, 10.3 months vs. 23.2 months) (PFS, p = 0.009; OS, p < 0.001). Although CP‐B was associated with a higher incidence of bleeding‐related events, the discontinuation rate due to adverse events did not differ from that of CP‐A. As a factor for stratifying CP‐B outcomes, significant differences in the PFS, OS and response rate were observed between mALBI grades ≤ 2b and 3 (PFS, p = 0.004; OS, p = 0.024; response rate, p = 0.001). In multivariate analysis, the mALBI grade (hazard ratio 95% CI: 2.388 1.186–4.810; p = 0.014) was extracted as a factor contributing to OS in patients with CP‐B. Conclusion Atez/Bev therapy demonstrated efficacy and safety in patients with CP‐B, especially when hepatic reserve is maintained within mALBI grade 2b.